PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 23:25:00·⟳ 抓取 23:25:20 +20s·⚡ 决策 08-27 23:27:30 +2m10s·61.3 天前
Rosen律所发布Aardvark Therapeutics (AARD)证券欺诈集体诉讼首席原告征集广告
本条信号是Rosen律所就已提起的证券集体诉讼发布的首席原告征集广告（Attorney Advertising），不包含任何新增事实。底层负面催化（ARD-101安全性问题）在Class Period结束日2026年5月14日前已公开，股价已从$17.94跌至$6.81（-62%）。该通知对股价无增量信息，不构成可交易事件。
📄 原文PR Newswire All News Releases↗ 原文
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardva…
不做 Aardvark Therapeutics（AARD.US）
本条信号是Rosen律所的首席原告征集广告（Attorney Advertising），不含任何新增事实。底层负面催化（ARD-101安全性问题）早在2026年5月已公开，股价已从$17.94跌至$6.81（-62%），信息已充分定价。日均成交额仅~$89万，流动性极差。无增量信息、无可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Rosen律所通过PR Newswire发布Aardvark Therapeutics (AARD.US)证券欺诈集体诉讼的首席原告征集通知。这是标准的律所广告，文中明确写道诉讼'已经提起'。底层负面事实（ARD-101安全性低于表述）在2026年5月14日（Class Period结束日）前已进入市场。股价从52周高点$17.94已跌至当前$6.81，跌幅62%。日均成交额仅约$89万，流动性极差。本条信号无任何新增事实、无方向性增量信息，不构成可交易催化。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 high ↗
消息传播链
- Rosen律所通过PR Newswire发布首席原告征集广告，这是证券集体诉讼中的标准律所营销行为，不含新增事实市场反应:AARD当日盘中无反应，价格持平于前收$6.81
先例如何影响了这次决策
对本次决策的影响:先例研究不适用：律所征集通知是例行广告，不构成可交易催化，无需历史先例定价
方向:不适用——本条信号无增量信息，无需先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 644 ms
{ - search_processed_events 成功 stock_tools HTTP · 4,740 ms
{"result": "search_processed_events:agent query=`aardvark therapeutics aard securities fraud lawsuit | ard-101 class action rosen law`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、12016 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 1,103 ms
{ - web_search 成功 Bing RSS(Tavily 降级后备) · 1,159 ms
web_search「Aardvark Therapeutics AARD ARD-101 clinical trial safety 2026」命中 5 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})：
原文全文
展开原文 · 4,181 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.
So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。